We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    VIB7734
Previous Study | Return to List | Next Study

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03817424
Recruitment Status : Completed
First Posted : January 25, 2019
Last Update Posted : August 13, 2020
Sponsor:
Information provided by (Responsible Party):
Viela Bio (acquired by Horizon Therapeutics) ( Viela Bio )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of escalating, multiple subcutaneous (SC) doses of VIB7734 in participants with Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Cutaneous Lupus Erythematosus Sjogren's Syndrome Systemic Sclerosis Polymyositis Dermatomyositis Drug: VIB7734 Drug: Placebo Phase 1

Detailed Description:
This study will have 3 periods: screening, treatment period, and extended follow-up. The screening period is 28 days. A total of 32 participants will be enrolled in 3 cohorts with 8 participants in Cohort 1, and 12 participants each in Cohorts 2 and 3. In Cohort 1, participants will be randomized in a 3:1 ratio to receive VIB7734 or matching placebo by injection every 4 weeks (q4w) for a total of 3 doses on Days 1, 29, and 57. In Cohorts 2 and 3, participants diagnosed with lupus only will be randomized in a 2:1 ratio to receive VIB7734 or matching placebo by injection q4w for 3 doses on Days 1, 29, and 57. Participants will be followed until at least Day 141. After the Day 141 visit, participants will exit the study if participants meets adequate plasmacytoid dendritic cells (pDCs). If an adequate pDC level does not meet at Day 141 visit, the participant will continue the follow-up for pDC repletion until they meet the protocol defined adequate pDC level or Day 337 visit has been reached.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
Actual Study Start Date : December 13, 2018
Actual Primary Completion Date : July 20, 2020
Actual Study Completion Date : July 20, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Cohort 1: VIB7734 Dose 1
Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
 Drug: VIB7734
Participants will receive VIB7734 via injection.
Other Name: MEDI7734
Experimental: Cohort 2: VIB7734 Dose 2
Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
 Drug: VIB7734
Participants will receive VIB7734 via injection.
Other Name: MEDI7734
Experimental: Cohort 3: VIB7734 Dose 3
Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
 Drug: VIB7734
Participants will receive VIB7734 via injection.
Other Name: MEDI7734
Placebo Comparator: Placebo
Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
 Drug: Placebo
Participants will receive placebo matching to VIB7734 via injection.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) [ Time Frame: Day 1 up to Day 337 ]
  2. Number of Participants With Adverse Events of Special Interest (AESIs) [ Time Frame: Day 1 up to Day 337 ]
  3. Number of Participants With Laboratory Abnormalities Reported as TEAEs [ Time Frame: Day 1 up to Day 337 ]
  4. Number of Participants With Vital Sign Abnormalities Reported as TEAEs [ Time Frame: Day 1 up to Day 337 ]
  5. Number of Participants With 12-Lead Electrocardiogram Abnormalities Reported as TEAEs [ Time Frame: Day 1 up to Day 337 ]

Secondary Outcome Measures :
  1. Maximum Observed Serum Concentration (Cmax) of VIB7734 Maximum Observed Serum Concentration (Cmax) of VIB7734 [ Time Frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253 ]
  2. Area Under the Concentration-time Curve (AUC) of VIB7734 [ Time Frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253 ]
  3. Systemic Clearance (CL) of VIB7734 [ Time Frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253 ]
  4. Terminal Half-life (t1/2) of VIB7734 [ Time Frame: Days 1 (pre-dose), 8, 15, 29 (pre-dose), 36, 43, 57 (pre-dose), 64, 71, 85, 113, 141, 169, 197, 225, and 253 ]
  5. Number of Participants With Positive Anti-Drug Antibodies of VIB7734 [ Time Frame: Day 1 up to Day 309 ]
  6. Change from Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score (Cohorts 2 and 3) [ Time Frame: Day 1 up to Day 253 ]
  7. Blood Levels of pDCs [ Time Frame: Day 1 up to Day 337 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants aged 18 through 75 years at the time of screening

  • Participants with at least one of the following diagnoses:

    1. Systemic Lupus Erythematosus
    2. Cutaneous lupus erythematosus, including acute CLE, subacute CLE, and discoid lupus erythematosus
    3. Sjogren's syndrome (for Cohort 1 only)
    4. Systemic sclerosis (for Cohort 1 only)
    5. Probable or definite polymyositis (for Cohort 1 only)
    6. Probable or definite dermatomyositis (for Cohort 1 only)
  • For Cohorts 2 and 3 only: Participants with CLASI activity score greater than or equal to (>=) 8 at both Visits 1 (screening) and 2 (baseline)
  • For Cohorts 2 and 3 only: a skin lesion amenable to punch skin biopsy and willingness of the participant to undergo skin biopsy at two time points
  • For Cohorts 2 and 3 only: photographs of skin lesions must be submitted for review to confirm the diagnosis of SLE or CLE with active skin lesions confirmation of the diagnosis by the central reviewer must be received prior to randomization
  • Females of childbearing potential and nonsterilized males who are ready to use protocol defined contraception methods

Exclusion Criteria:

  • Severe manifestations of the diseases under study that could impact the participant safety
  • Known history of a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection, a positive result for HIV infection, splenectomy, or any underlying condition that predisposes the participant to infection
  • At screening, have adequate central laboratory test results: aspartate transaminase greater than (>) 2.5 x upper limit of normal (ULN); alanine transaminase >2.5 x ULN; total bilirubin 1.5 x ULN; total immunoglobulin < 500 gram/decilitre; neutrophil count less than (<) 1,000/μL; platelet count < 85,000/μL; haemoglobin < 10 g/dL; glycosylated haemoglobin > 8 percent (%); total lymphocyte count < 300 cells/mm^3; glomerular filtration rate < 50 mL/min/1.73 m^2; plasmacytoid dendritic cells (pDC) level < 0.02% of peripheral blood mononuclear cells (PBMCs)
  • Positive test for chronic hepatitis B infection at screening and for hepatitis C virus antibody
  • History of or active tuberculosis (TB), or a positive QuantiFERON®-TB Gold test at screening; a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection, a positive result for HIV infection per central laboratory; cancer; clinically significant cardiac disease
  • Herpes zoster infection within 3 months before randomization and/or any severe herpes virus family infection at any time prior to randomization
  • Any acute illness or evidence of clinically significant active infection, such as fever >= 38.0 degrees Celsius (>= 100.5 degrees Fahrenheit) at screening (Visit 1) or Day 1 (Visit 2)
  • Cohorts 2 and 3 only: use of Group 1 (super-high potency) or Group 2 (high potency) topical corticosteroids
  • Receipt of a live-attenuated vaccine within 4 weeks prior to Day 1
  • Cohorts 2 and 3 only: have received changing doses of mycophenolate mofetil, methotrexate, leflunomide, azathioprine, or non-steroidal topical immunosuppressants within 28 days before study Day 1 or changing doses of oral or topical corticosteroids within 14 days before study Day 1
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03817424


Locations
Layout table for location information
United States, Alabama
Viela Bio Investigative Site
Anniston, Alabama, United States, 36201
Viela Bio Investigative Site
Birmingham, Alabama, United States, 35294
United States, California
Viela Bio Investigative Site
Los Angeles, California, United States, 90022
Viela Bio Investigative Site
Upland, California, United States, 91786
United States, Connecticut
Viela Bio Investigative Site
Danbury, Connecticut, United States, 06810
United States, Florida
Viela Bio Investigative Site
Fort Lauderdale, Florida, United States, 33309
Viela Bio Investigative Site
Hialeah, Florida, United States, 33016
Viela Bio Investigative Site
Jacksonville, Florida, United States, 32216
Viela Bio Investigative Site
Miami Lakes, Florida, United States, 33014
Viela Bio Investigative Site
Saint Petersburg, Florida, United States, 33710
United States, Georgia
Viela Bio Investigative Site
Lawrenceville, Georgia, United States, 30046
United States, New York
Viela Bio Investigative Site
Great Neck, New York, United States, 11021
United States, North Carolina
Viela Bio Investigative Site
Charlotte, North Carolina, United States, 28204
Viela Bio Investigative Site
Durham, North Carolina, United States, 27713
United States, Pennsylvania
Viela Bio Investigative Site
Duncansville, Pennsylvania, United States, 16635
Viela Bio Investigative Site
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Viela Bio Investigative Site
Memphis, Tennessee, United States, 38119
United States, Texas
Viela Bio Investigative Site
Allen, Texas, United States, 75013
Viela Bio Investigative Site
Mesquite, Texas, United States, 75150
Poland
Viela Bio Investigative Site
Białystok, Poland
Viela Bio Investigative Site
Bydgoszcz, Poland
Viela Bio Investigative Site
Kraków, Poland
Viela Bio Investigative Site
Poznań, Poland
Viela Bio Investigative Site
Rzeszów, Poland
Viela Bio Investigative Site
Warsaw, Poland
Viela Bio Investigative Site
Wrocław, Poland
Spain
Viela Bio Investigative Site
Barcelona, Spain
Viela Bio Investigative Site
Bilbao, Spain
Viela Bio Investigative Site
Madrid, Spain
Viela Bio Investigative Site
Sevilla, Spain
Sponsors and Collaborators
Viela Bio
Investigators
Layout table for investigator information
Study Director: Jack Ratchford, MD Viela Bio
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Viela Bio
ClinicalTrials.gov Identifier: NCT03817424    
Other Study ID Numbers: VIB7734.P1b.S1
2018-003767-60 ( EudraCT Number )
First Posted: January 25, 2019    Key Record Dates
Last Update Posted: August 13, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sjogren's Syndrome
Dermatomyositis
Polymyositis
Lupus Erythematosus, Systemic
Scleroderma, Systemic
Scleroderma, Diffuse
Lupus Erythematosus, Cutaneous
Syndrome
Sclerosis
Disease
Pathologic Processes
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Skin Diseases
 Arthritis, Rheumatoid
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Xerostomia
Salivary Gland Diseases
Mouth Diseases
Stomatognathic Diseases
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Myositis
Muscular Diseases
Neuromuscular Diseases